vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $179.8M, roughly 1.1× Vita Coco Company, Inc.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 17.0%, a 32.5% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 37.3%). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 11.7%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
COCO vs TMP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $194.8M |
| Net Profit | $30.5M | $96.2M |
| Gross Margin | 39.9% | — |
| Operating Margin | 18.7% | 71.7% |
| Net Margin | 17.0% | 49.4% |
| Revenue YoY | 37.3% | 152.7% |
| Net Profit YoY | 61.4% | 388.9% |
| EPS (diluted) | $0.50 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $194.8M | ||
| Q3 25 | $182.3M | $87.4M | ||
| Q2 25 | $168.8M | $82.6M | ||
| Q1 25 | $130.9M | $81.7M | ||
| Q4 24 | $127.3M | $77.1M | ||
| Q3 24 | $132.9M | $76.6M | ||
| Q2 24 | $144.1M | $72.7M |
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | $96.2M | ||
| Q3 25 | $24.0M | $23.7M | ||
| Q2 25 | $22.9M | $21.5M | ||
| Q1 25 | $18.9M | $19.7M | ||
| Q4 24 | $3.4M | $19.7M | ||
| Q3 24 | $19.3M | $18.6M | ||
| Q2 24 | $19.1M | $15.7M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 36.3% | — | ||
| Q1 25 | 36.7% | — | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 38.8% | — | ||
| Q2 24 | 40.8% | — |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 71.7% | ||
| Q3 25 | 15.3% | 35.6% | ||
| Q2 25 | 14.9% | 34.2% | ||
| Q1 25 | 14.7% | 31.6% | ||
| Q4 24 | 3.4% | 33.4% | ||
| Q3 24 | 15.5% | 32.0% | ||
| Q2 24 | 20.8% | 28.3% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | 49.4% | ||
| Q3 25 | 13.2% | 27.1% | ||
| Q2 25 | 13.6% | 26.0% | ||
| Q1 25 | 14.4% | 24.1% | ||
| Q4 24 | 2.6% | 25.5% | ||
| Q3 24 | 14.5% | 24.3% | ||
| Q2 24 | 13.2% | 21.6% |
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $6.72 | ||
| Q3 25 | $0.40 | $1.65 | ||
| Q2 25 | $0.38 | $1.50 | ||
| Q1 25 | $0.31 | $1.37 | ||
| Q4 24 | $0.06 | $1.39 | ||
| Q3 24 | $0.32 | $1.30 | ||
| Q2 24 | $0.32 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $352.2M | $938.4M |
| Total Assets | $488.3M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $132.8M | ||
| Q3 25 | $203.7M | $193.5M | ||
| Q2 25 | $167.0M | $212.6M | ||
| Q1 25 | $153.6M | $193.1M | ||
| Q4 24 | $164.7M | $134.4M | ||
| Q3 24 | $156.7M | $132.3M | ||
| Q2 24 | $150.1M | $70.9M |
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $938.4M | ||
| Q3 25 | $323.7M | $788.8M | ||
| Q2 25 | $296.9M | $761.8M | ||
| Q1 25 | $277.9M | $741.4M | ||
| Q4 24 | $258.8M | $713.4M | ||
| Q3 24 | $252.1M | $719.9M | ||
| Q2 24 | $232.0M | $674.6M |
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $8.7B | ||
| Q3 25 | $461.3M | $8.5B | ||
| Q2 25 | $421.1M | $8.4B | ||
| Q1 25 | $384.0M | $8.2B | ||
| Q4 24 | $362.4M | $8.1B | ||
| Q3 24 | $353.1M | $8.0B | ||
| Q2 24 | $323.0M | $7.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $38.9M |
| Free Cash FlowOCF − Capex | — | $31.9M |
| FCF MarginFCF / Revenue | — | 16.4% |
| Capex IntensityCapex / Revenue | — | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $38.9M | ||
| Q3 25 | $39.1M | $34.9M | ||
| Q2 25 | $21.8M | $18.9M | ||
| Q1 25 | $-9.8M | $22.2M | ||
| Q4 24 | $6.9M | $95.0M | ||
| Q3 24 | $9.3M | $21.2M | ||
| Q2 24 | $26.9M | $27.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | $31.9M | ||
| Q3 25 | $35.6M | $33.9M | ||
| Q2 25 | $20.9M | $18.3M | ||
| Q1 25 | $-10.4M | $20.9M | ||
| Q4 24 | $6.8M | $88.8M | ||
| Q3 24 | $8.9M | $18.9M | ||
| Q2 24 | $26.6M | $26.3M |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 16.4% | ||
| Q3 25 | 19.6% | 38.8% | ||
| Q2 25 | 12.4% | 22.1% | ||
| Q1 25 | -7.9% | 25.5% | ||
| Q4 24 | 5.3% | 115.1% | ||
| Q3 24 | 6.7% | 24.7% | ||
| Q2 24 | 18.5% | 36.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 3.6% | ||
| Q3 25 | 1.9% | 1.1% | ||
| Q2 25 | 0.6% | 0.8% | ||
| Q1 25 | 0.4% | 1.7% | ||
| Q4 24 | 0.1% | 8.1% | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.2% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | 0.40× | ||
| Q3 25 | 1.63× | 1.47× | ||
| Q2 25 | 0.95× | 0.88× | ||
| Q1 25 | -0.52× | 1.13× | ||
| Q4 24 | 2.05× | 4.82× | ||
| Q3 24 | 0.48× | 1.14× | ||
| Q2 24 | 1.41× | 1.74× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
TMP
Segment breakdown not available.
